Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | BRD1 | O95696 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | IL1RN | P18510 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10774342 | 0.83 | KMT2A (0.65) | ALDH1A1MAPTPKMLMNAKMT2A | |
| SCHEMBL3332937 | 0.83 | CA12 (0.65) | ALDH1A1MAPTLMNAPOLBKMT2A | |
| SCHEMBL751419 | 0.83 | CYP19A1 (0.63) | ALDH1A1MAPTPKMLMNAPGR | |
| SCHEMBL5037019 | 0.81 | MAPT (0.58) | ALDH1A1MAPTPKMLMNASMN1; SMN2 | |
| SCHEMBL965226 | 0.81 | KEAP1 (0.66) | ALDH1A1MAPTPKMLMNASMN1; SMN2 | |
| SCHEMBL5041834 | 0.80 | MEN1 (0.55) | ALDH1A1MAPTPKMPOLBKMT2A | |
| SCHEMBL28821888 | 0.80 | UQCRB (0.54) | ALDH1A1MAPTPKMLMNASMN1; SMN2 | |
| SCHEMBL5046841 | 0.80 | HSD17B2 (0.55) | ALDH1A1PKMSMN1; SMN2PGRKMT2A | |
| SCHEMBL5202188 | 0.79 | CA1 (0.60) | ALDH1A1MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL5044708 | 0.79 | CYP19A1 (0.66) | ALDH1A1MAPTPKMLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250325-B1 | PHENANTHRIDINE-N-OXIDES | NYCOMED GMBH (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-6630483-B2 | Phenanthridine-N-oxides | ALTANA PHARMA AG (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20030105123-A1 | For therapy of respiratory system disorders | ALTANA PHARMA AG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1250325-A1 | PHENANTHRIDINE-N-OXIDES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| EP-0889886-B1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | ALTANA PHARMA AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001051470-A1 | PHENANTHRIDINE-N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-6127378-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105123-A1 | For therapy of respiratory system disorders | CHRM3, CYP11B1, CYP11B2 | ALDH1A1 1029/4885MAPT 4639/4885PKM 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.